{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:54:59Z","timestamp":1792648499068,"version":"4.5.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.<\/jats:p>","DOI":"10.1093\/cid\/ciz364","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T23:27:54Z","timestamp":1556580474000},"page":"1812-1816","source":"Crossref","is-referenced-by-count":78,"title":["Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections"],"prefix":"10.1093","volume":"69","author":[{"given":"Valerie J","family":"Waters","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Kidd","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Canton","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal and Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel B","family":"Ekkelenkamp","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Krogh","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Rigshospitalet, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"LiPuma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, Prince Charles Hospital and QIMR Berghofer Medical Research Institute, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Stuart","family":"Elborn","sequence":"additional","affiliation":[{"name":"Imperial College Hospital, Queen\u2019s University Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A","family":"Flume","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R","family":"VanDevanter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Department of Pathology-Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Antimicrobial Resistance International Working Group in Cystic Fibrosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Bullington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Regis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Maples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Martiniano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"McColley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Muhlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Saiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tunney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"2019103013435296400_CIT0001","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"2019103013435296400_CIT0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1126\/science.2997931","article-title":"Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker","volume":"230","author":"Tsui","year":"1985","journal-title":"Science"},{"key":"2019103013435296400_CIT0003","volume-title":"Patient registry report","author":"Cystic Fibrosis Foundation","year":"2016"},{"key":"2019103013435296400_CIT0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-112717-094536","article-title":"Cystic fibrosis: emerging understanding and therapies","volume":"70","author":"Rey","year":"2019","journal-title":"Annu Rev Med"},{"key":"2019103013435296400_CIT0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"2019103013435296400_CIT0006","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1586\/14787210.4.5.807","article-title":"Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues","volume":"4","author":"Waters","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019103013435296400_CIT0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nm.2715","article-title":"Cystic fibrosis: a mucosal immunodeficiency syndrome","volume":"18","author":"Cohen","year":"2012","journal-title":"Nat Med"},{"key":"2019103013435296400_CIT0008","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00580-11","article-title":"The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests","volume":"49","author":"Doern","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2019103013435296400_CIT0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"2019103013435296400_CIT0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ppul.21521","article-title":"Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"2019103013435296400_CIT0011","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2019103013435296400_CIT0012","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrd4000","article-title":"Applying insights from biofilm biology to drug development\u2014can a new approach be developed?","volume":"12","author":"Bjarnsholt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2019103013435296400_CIT0013","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMcibr021776","article-title":"Biofilms, antimicrobial resistance, and airway infection","volume":"347","author":"Prince","year":"2002","journal-title":"N Engl J Med"},{"key":"2019103013435296400_CIT0014","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1128\/JB.01651-09","article-title":"Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis","volume":"192","author":"Mulcahy","year":"2010","journal-title":"J Bacteriol"},{"key":"2019103013435296400_CIT0015","doi-asserted-by":"crossref","first-page":"e1003741","DOI":"10.1371\/journal.pgen.1003741","article-title":"Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators","volume":"9","author":"Marvig","year":"2013","journal-title":"PLoS Genet"},{"key":"2019103013435296400_CIT0016","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"2019103013435296400_CIT0017","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1469-0691.2010.03250.x","article-title":"Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance","volume":"16","author":"Oliver","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2019103013435296400_CIT0018","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2019103013435296400_CIT0019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2018.08.014","article-title":"Defining antimicrobial resistance in cystic fibrosis","volume":"17","author":"Kidd","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2019103013435296400_CIT0020","doi-asserted-by":"crossref","first-page":"e00981-15","DOI":"10.1128\/mBio.00981-15","article-title":"Selective sweeps and parallel pathoadaptation drive Pseudomonas aeruginosa evolution in the cystic fibrosis lung","volume":"6","author":"Diaz Caballero","year":"2015","journal-title":"MBio"},{"key":"2019103013435296400_CIT0021","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chom.2015.07.006","article-title":"Regional isolation drives bacterial diversification within cystic fibrosis lungs","volume":"18","author":"Jorth","year":"2015","journal-title":"Cell Host Microbe"},{"key":"2019103013435296400_CIT0022","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ppul.20220","article-title":"How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?","volume":"39","author":"VanDevanter","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"2019103013435296400_CIT0023","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1073\/pnas.1120577109","article-title":"Decade-long bacterial community dynamics in cystic fibrosis airways","volume":"109","author":"Zhao","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019103013435296400_CIT0024","doi-asserted-by":"crossref","first-page":"10241","DOI":"10.1038\/srep10241","article-title":"Lung microbiota across age and disease stage in cystic fibrosis","volume":"5","author":"Coburn","year":"2015","journal-title":"Sci Rep"},{"key":"2019103013435296400_CIT0025","volume-title":"Cumitech 43, cystic fibrosis microbiology","author":"Gilligan","year":"2006"},{"key":"2019103013435296400_CIT0026","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1513\/AnnalsATS.201407-303ED","article-title":"Expanding our understanding of respiratory microbiota in cystic fibrosis","volume":"11","author":"LiPuma","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2019103013435296400_CIT0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41522-017-0035-0","article-title":"Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance","volume":"3","author":"Beaudoin","year":"2017","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2019103013435296400_CIT0028","volume-title":"Performance standards for antimicrobial susceptibility testing. M-100S","author":"Clinical and Laboratory Standards Institute","year":"2018","edition":"28"},{"key":"2019103013435296400_CIT0029","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1046\/j.1469-0691.2000.00178.x","article-title":"EUCAST definitive document E.DEF 2.1, August 2000: determination of antimicrobial susceptibility test breakpoints","volume":"6","author":"European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"2019103013435296400_CIT0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2019103013435296400_CIT0031","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2019103013435296400_CIT0032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"key":"2019103013435296400_CIT0033","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"2019103013435296400_CIT0034","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1378\/chest.128.2.912","article-title":"Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients","volume":"128","author":"Wagner","year":"2005","journal-title":"Chest"},{"key":"2019103013435296400_CIT0035","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.01011-06","article-title":"Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-\/-) mice","volume":"51","author":"Hoffmann","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2019103013435296400_CIT0036","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0954-6111(11)70023-3","article-title":"Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis","volume":"105","author":"VanDevanter","year":"2011","journal-title":"Respir Med"},{"key":"2019103013435296400_CIT0037","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"2019103013435296400_CIT0038","doi-asserted-by":"crossref","first-page":"e0170622","DOI":"10.1371\/journal.pone.0170622","article-title":"Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients","volume":"12","author":"Cox","year":"2017","journal-title":"PLoS One"},{"key":"2019103013435296400_CIT0039","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"Tunney","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2019103013435296400_CIT0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.aaf8156","article-title":"Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium","volume":"354","author":"Bryant","year":"2016","journal-title":"Science"},{"key":"2019103013435296400_CIT0041","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"key":"2019103013435296400_CIT0042","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ppul.23825","article-title":"Nontuberculous mycobacteria in cystic fibrosis: updates and the path forward","volume":"52","author":"Martiniano","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2019103013435296400_CIT0043","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2019103013435296400_CIT0044","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2019103013435296400_CIT0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur Respir J"},{"key":"2019103013435296400_CIT0046","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkm481","article-title":"Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis","volume":"61","author":"Etherington","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019103013435296400_CIT0047","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/JCM.42.5.1915-1922.2004","article-title":"Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis","volume":"42","author":"Moskowitz","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2019103013435296400_CIT0048","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jac\/dki338","article-title":"Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection","volume":"56","author":"Moskowitz","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2019103013435296400_CIT0049","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms","volume":"37","author":"Ceri","year":"1999","journal-title":"J Clin Microbiol"},{"key":"2019103013435296400_CIT0050","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.46.4.1105-1107.2002","article-title":"Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis","volume":"46","author":"Saiman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019103013435296400_CIT0051","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/JCM.40.11.4172-4179.2002","article-title":"Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis","volume":"40","author":"Aaron","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2019103013435296400_CIT0052","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1164\/ajrccm.161.4.9907147","article-title":"Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia","volume":"161","author":"Aaron","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2019103013435296400_CIT0053","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ppul.21350","article-title":"Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection","volume":"46","author":"Moskowitz","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2019103013435296400_CIT0054","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2014.09.013","article-title":"Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients","volume":"14","author":"Yau","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2019103013435296400_CIT0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"key":"2019103013435296400_CIT0056","first-page":"163","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"key":"2019103013435296400_CIT0057","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/AAC.01720-16","article-title":"Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019103013435296400_CIT0058","doi-asserted-by":"crossref","first-page":"12512","DOI":"10.1038\/s41598-018-30972-y","article-title":"Mutations causing low level antibiotic resistance ensure bacterial survival in antibiotic-treated hosts","volume":"8","author":"Frimodt-M\u00f8ller","year":"2018","journal-title":"Sci Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz364\/28839544\/ciz364.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/10\/1812\/30327445\/ciz364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/10\/1812\/30327445\/ciz364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T23:40:39Z","timestamp":1663371639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/10\/1812\/5485863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5,6]]},"published-print":{"date-parts":[[2019,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz364","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,15]]},"published":{"date-parts":[[2019,5,6]]}}}